The Indian Council of Medical Research (ICMR) successfully organized its 1st Annual Clinical Trial Meet 2026 on May 20, 2026, under the theme “International Clinical Trials Day: Focus on Integrative Medicine Clinical Trials,” marking a significant milestone for India’s clinical research ecosystem. The event featured groundbreaking findings from ICMR’s multicentric Phase III trial on iron deficiency anemia, showing Ayurvedic formulations were therapeutically equivalent to standard iron-folic acid therapy in nearly 4,000 non-pregnant women.
ICMR launched two major reports: “Advancing First-in-Human Phase 1 Clinical Trials in India” and “Operational Guidelines for Single Ethics Review of Multicentre Research” to strengthen regulatory pathways and harmonize ethical reviews nationwide. India’s New Drugs and Clinical Trials (Amendment) Rules 2026 reduced approval timelines from 90 to 45 working days, significantly improving ease of doing business for pharmaceutical companies.
The 17th Annual Clinical Trials Summit 2026 is scheduled for June 10–11 at World Trade Center Mumbai, serving as India’s premier platform for exploring decentralized trials, AI-driven research, and future advancements in clinical trials.
International Updates
The United Kingdom implemented its most significant clinical trials reform in two decades on April 28, 2026, with The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 creating streamlined approvals through a codified Combined Review process. The reforms emphasize risk-proportionate approaches, expedited pathways for low-risk trials, and renewed focus on patient diversity and inclusion.
Global Clinical Trials Connect 2026 will convene leading experts focusing on adaptive trial designs, AI-powered analytics, and patient-centric research strategies, bringing together global leaders, clinical researchers, and technology pioneers. Euro Clinical Trials 2026 is scheduled for June 29–30, 2026 in London, UK, fostering collaboration among international clinical research experts.
International Clinical Trials Day was celebrated on May 20, 2026 worldwide with the theme “Stronger Together: Advanced Therapy Clinical Trials Without Borders,” emphasizing multinational clinical research collaboration and patient-centric approaches
The Clinical and Research Updates section monitors drug and phase across India's pharmaceutical sector. Significant developments around trial continue to draw attention from regulators, investors, and industry professionals, reflecting the dynamic pace of change in this space.
Recent coverage has drawn from 아시아경제, Bioengineer.org, and Everyday Health, among other publications. This section is updated as new stories emerge, ensuring readers have access to the most current information shaping this part of the pharmaceutical landscape.
For authoritative reference, ClinicalTrials.gov and WHO ICTRP publish official guidance and regulatory documentation relevant to these topics. Peer-reviewed research and clinical data can be accessed through CTRI India.
Showing 30 articles
-
[Click e-Stock] "Abion Confirms Vavamakep Clinical Results... Next-Generation iRAC Platform Boosts Oncology Drug Value"
[Click e-Stock] "Abion Confirms Vavamakep Clinical Results... Next-Generation iRAC Platform Boosts Oncology Drug Value" 아시아경제
-
Insilico Medicine to Present Phase 1 ISM6331 Results at ESMO 2026
Insilico Medicine to Present Phase 1 ISM6331 Results at ESMO 2026 Bioengineer.org
-
Simtriyo (Centanafadine) for ADHD: How It Works and Side Effects
Simtriyo (Centanafadine) for ADHD: How It Works and Side Effects Everyday Health
-
Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol-Use Disorder Trial
Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol-Use Disorder Trial MedCity News
-
GSK set to slash billions in costs over next three years by embracing AI sparking fears of a jobs bloodbath
GSK set to slash billions in costs over next three years by embracing AI sparking fears of a jobs bloodbath This is Money
-
A Team Approach to ADPKD Care | Newswise
A Team Approach to ADPKD Care | Newswise Newswise
-
Topline results from LiBBY trial show THC/CBD combination significantly reduces agitation for people with dementia at end of life
Topline results from LiBBY trial show THC/CBD combination significantly reduces agitation for people with dementia at end of life EurekAlert!
-
CBD and THC Reduce Dementia Agitation
CBD and THC Reduce Dementia Agitation Neuroscience News
-
Children’s Hospital Los Angeles Study Finds GLP-1 Medications May Improve Weight Loss After Bariatric Surgery in Adolescents | Newswise
Children’s Hospital Los Angeles Study Finds GLP-1 Medications May Improve Weight Loss After Bariatric Surgery in Adolescents | Newswise Newswise
-
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results TMX Newsfile
-
Clinical Trials Provider Soars, Clears Buy Point On Solid Q2 Results
Clinical Trials Provider Soars, Clears Buy Point On Solid Q2 Results Investor's Business Daily
-
Growth Monitoring Study Demonstrates Healthy Growth and Safety in Infants Fed A2-Type Protein Formula
Growth Monitoring Study Demonstrates Healthy Growth and Safety in Infants Fed A2-Type Protein Formula markets.businessinsider.com
-
Dysautonomia conference centers biomarkers and post-exertional malaise
Dysautonomia conference centers biomarkers and post-exertional malaise The Sick Times
-
Research updates, July 28
Research updates, July 28 The Sick Times
-
The a2 Milk Company Advances Global Leadership in Beta-Casein Science with New Research Presented at NUTRITION 2026
The a2 Milk Company Advances Global Leadership in Beta-Casein Science with New Research Presented at NUTRITION 2026 Macau Business
-
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research The New York Times
-
Kalshi is expanding online betting in drug R&D — unless detractors can stop it
Kalshi is expanding online betting in drug R&D — unless detractors can stop it Pharma Voice
-
FDA Releases Final Guidances to Expand Participation in Cancer Clinical Trials
FDA Releases Final Guidances to Expand Participation in Cancer Clinical Trials The ASCO Post
-
A Story of Bad Science: How Defenders of Antidepressant Efficacy Make Their Case
A Story of Bad Science: How Defenders of Antidepressant Efficacy Make Their Case Mad In America
-
Eating Within a Nine-Hour Window May Help Protect Aging Brains, New Rutgers Study Suggests
Eating Within a Nine-Hour Window May Help Protect Aging Brains, New Rutgers Study Suggests International Business Times Australia
-
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer The Manila Times
-
Cheiron Raises $8 Million Seed Round Led By Menlo Ventures For AI-Native Drug Development Platform
Cheiron Raises $8 Million Seed Round Led By Menlo Ventures For AI-Native Drug Development Platform Pulse 2.0
-
Clearmind Medicine Completes Treatment of All Participants in Part A of Phase I/II AUD Trial for CMND-100
Clearmind Medicine Completes Treatment of All Participants in Part A of Phase I/II AUD Trial for CMND-100 Quiver Quantitative
-
24 Participants Complete Treatment in Clearmind's Alcohol Use Disorder Trial
24 Participants Complete Treatment in Clearmind's Alcohol Use Disorder Trial Stock Titan
-
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) The Manila Times
-
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder The Manila Times
-
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML The Manila Times
-
Ebola outbreak: 1,407 deaths as opaganib discussions continue
Ebola outbreak: 1,407 deaths as opaganib discussions continue Stock Titan
-
ViiV Healthcare’s two-drug regimen as good as Biktarvy, study finds
ViiV Healthcare’s two-drug regimen as good as Biktarvy, study finds Clinical Trials Arena
-
Integrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trial
Integrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trial Nature